Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamorolone in boys with Duchenne Muscular Dystrophy
NCT05185622Phase 2Completed
- Sponsor
- Santhera Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of vamorolone in Duchenne muscular dystrophy (DMD), sponsored by Santhera Pharmaceuticals. Started Mar 2022; status: completed.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05185622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05185622.